In EP Edge® Journal Watch Issue 37, September 2026, Dr. Sharma reviews 13 important studies in cardiac electrophysiology, with a focus on what the data actually mean for clinical practice. This episode goes beyond abstracts and headline results to examine why each study was performed, the clinical question investigators were trying to answer, the methodology used, the statistics behind the major findings, important limitations, and what the results may mean for electrophysiologists going forward. This episode begins with a major theme in contemporary atrial fibrillation care: left atrial appendage occlusion and stroke prevention. First, we examine the mechanistic study “Left Atrial Appendage Thrombosis in Patients With Atrial Fibrillation” from Ji Zhou and colleagues. Histologic examination of surgically removed appendages from LAAOS III participants identified microscopic thrombi in the trabecular crypts, raising important questions about persistent local thrombogenicity despite anticoagulation and providing biological context for why mechanical left atrial appendage exclusion may provide additional protection in selected patients. We then turn to two important meta-analyses comparing left atrial appendage occlusion with medical therapy. The contemporary randomized evidence suggests that LAAO may substantially reduce nonprocedural bleeding, but the possibility of a modest increase in ischemic stroke remains unresolved. The discussion focuses on why LAAO should be viewed as a trade-off between procedural risk, long-term bleeding exposure, and stroke protection rather than simply as an equivalent replacement for direct oral anticoagulation. The episode then examines the ADVANCE LAA study, led by Dhanunjaya Lakkireddy, evaluating Amulet implantation in patients who failed Watchman anatomical screening. Despite more challenging left atrial appendage anatomy, Amulet implantation remained highly successful, reinforcing an important practical concept: failure of one device geometry does not necessarily mean failure of the LAAO strategy. Next, we review randomized evidence comparing direct oral anticoagulants versus dual antiplatelet therapy after left atrial appendage closure. The pooled data showed markedly lower device-related thrombus with DOAC-based therapy and, perhaps surprisingly, less major and minor bleeding than with DAPT. The clinical question is no longer simply whether anticoagulation can be stopped, but what antithrombotic strategy provides the safest bridge through the early device-healing period. The second major theme is pulsed field ablation safety and lesion durability. A major Circulation study led by Enrico Ferro compared neurological outcomes after pulsed field ablation and radiofrequency ablation. Although absolute stroke and TIA rates remained low, PFA was associated with a higher 30-day neurovascular event rate in this observational registry. Dr. Sharma discusses the difference between relative and absolute risk, why propensity adjustment cannot eliminate residual confounding, and why rapid adoption of PFA makes rigorous post-market safety surveillance essential. We then examine “Transmurality and Autonomic Effects of Pulsed Field Ablation on the Mitral Isthmus” by Apoor Patel and colleagues. Using direct vein of Marshall recordings, investigators demonstrated that apparent endocardial mitral isthmus block frequently concealed persistent epicardial conduction. PFA alone achieved complete block in fewer than half of patients, while vein of Marshall ethanol infusion substantially increased block rates. The study also demonstrated that PFA generally spared local parasympathetic innervation, whereas ethanol infusion produced denervation. The findings raise important questions about how we define lesion completeness in the PFA era. The episode then moves to atrial fibrillation detection and prediction. The PAVA score, developed by Baptiste Maille and colleagues, attempts to identify patients at lower likelihood of AF detection after cryptogenic stroke using premature atrial contractions, age, significant valvular disease, and left atrial enlargement. The score performed well in internal validation but less strongly in external validation, highlighting why prediction models should be judged by more than their best AUC. We also discuss the study “Wearable smartwatches for atrial fibrillation detection and burden estimation after ablation: comparison with continuous monitoring.” Using continuous implantable cardiac monitor data from CIRCA-DOSE, investigators simulated Apple Watch and Fitbit AF-detection algorithms. Smartwatch strategies detected substantially more recurrence than conventional short Holter monitoring, while wearable-estimated AF burden correlated closely with continuous monitoring. The episode examines the critical distinction between correlation and agreement, and why simulation is not the same as prospective real-world validation. Another study evaluates the neutrophil-to-lymphocyte ratio as a predictor of postoperative atrial fibrillation after cardiac surgery. Elevated NLR was associated with postoperative AF, supporting an inflammatory component to arrhythmogenesis, but its standalone diagnostic performance was only moderate. This provides a useful example of why a statistically significant biomarker association does not automatically translate into a clinically useful prediction test. Two practical ventricular arrhythmia studies then return the discussion to the 12-lead ECG. Masafumi Sugawara and colleagues demonstrate that comparing the PVC QRS axis with the patient’s baseline sinus-rhythm axis may help distinguish true para-Hisian PVCs from RVOT and LVOT mimics. Rather than interpreting the ectopic beat in isolation, the study suggests that the patient’s baseline electrical orientation should become part of PVC localization. Yoshihisa Naruse and colleagues introduce the V6R/V4R index, a simple ECG parameter designed to distinguish aortic cusp ventricular arrhythmias from non-cusp LVOT origins. The index may help determine where mapping should begin, although the paper contains inconsistencies in the reported diagnostic performance that deserve careful interpretation. Finally, the episode explores whether SGLT2 inhibitors may reduce sudden cardiac death. Andrea Matteucci and colleagues pooled adjudicated randomized evidence involving empagliflozin and dapagliflozin across nearly 59,000 participants. SGLT2 inhibition was associated with approximately an 18 percent reduction in the odds of sudden cardiac death, with consistent results across the included trials. The key unanswered question is mechanism. Does this reflect a direct antiarrhythmic effect, or is sudden death reduced indirectly through improvements in heart failure, myocardial energetics, fibrosis, renal function, and overall cardiovascular stability? Throughout the episode, Dr. Sharma focuses on the difference between statistical significance and clinical significance, association versus prediction, relative versus absolute risk, and the practical implications of these studies for electrophysiology practice. Topics include: atrial fibrillation, left atrial appendage occlusion, Watchman, Amulet, DOACs, DAPT, device-related thrombus, pulsed field ablation, PFA safety, stroke after AF ablation, mitral isthmus ablation, vein of Marshall ethanol infusion, wearable AF monitoring, Apple Watch, implantable loop recorders, cryptogenic stroke, PAVA score, postoperative atrial fibrillati...
